FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
Information source: University of North Carolina, Chapel Hill
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Autism Spectrum Disorder
Intervention: Aripiprazole (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University of North Carolina, Chapel Hill Official(s) and/or principal investigator(s): Linmarie Sikich, MD, Principal Investigator, Affiliation: University of North Carolina Gabriel Dichter, PhD, Principal Investigator, Affiliation: University of North Carolina and Duke University Cheryl O Alderman, BS, Study Director, Affiliation: University of North Carolina, Chapel Hill
Summary
This is an 8 week research study of aripiprazole (abilify) which is used to reduce irritable
behaviors in autism spectrum disorders. All participants will receive active study
medication. Participants will also receive diagnostic and cognitive evaluations at no cost.
Participants will be required to undergo two fMRI (functional magnetic resonance imaging
scans) where we will take pictures of your brain while performing simple tasks.
Clinical Details
Official title: Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms
Study design: Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version
Secondary outcome: Total Repetitive Behavior Scale - Revised (RBS_R)
Eligibility
Minimum age: 10 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- male or female of any race or ethnicity
- ambulatory status (outpatient) at time of consent
- age 10-55 inclusive at time of consent
- clinical diagnosis of autism spectrum disorder and meets screening criteria on the
Social Communication Questionnaire as well as either the Autism Diagnostic
Observation Schedule (ADOS) or the Autism Diagnostic Interview-Revised (ADI-R)
administered by raters trained to research reliability.
- estimated IQ greater than 70 and capable of making an informed decision based on
assessment of their understanding and judgment
- Children's Yale-Brown Obsessive Compulsive Scale: Modified for Pervasive
Developmental Disorders (PDD-CYBOCS) > 8 as assessed during telephone screening.
- Free of psychoactive medication for at least: one month for fluoxetine; two weeks for
other SSRIs and neuroleptics; and five days for stimulants prior to MRI scanning
[excepting stable doses (greater than three months duration) of anticonvulsant
medication for seizure disorder]
- Currently taking psychoactive medication that is not providing sufficient relief of
repetitive behaviors and willing to discontinue all psychoactive medication for the
duration of the study.
- Judged reliable for medication compliance and agreeing to keep follow-up study
appointments.
Exclusion Criteria:
- Age less than 10 years or greater than 55 years at time of consent
- Estimated IQ less than 70
- Uncontrolled epilepsy (seizure within 6 months prior to consent)
- Presence of medical conditions that might interfere with participation, or where
participation would be contraindicated.
- History of neurological injury: head trauma, poorly-controlled seizure disorder
(seizure within the preceding six months), stroke, prior neurosurgery, or under the
care of a neurologist or neurosurgeon as determined by interview
- History of claustrophobia
- Implanted or irremovable metal in the body (including certain tattoos and permanent
make-up).
- Current pregnancy in females
- Inability to communicate satisfactorily and directly (without a translator) in
English
- Medical contraindications to aripiprazole therapy as determined by history (including
induction of neuroleptic malignant syndrome, dystonic reaction, or known drug
allergy)
- Ongoing need for psychoactive medication other than study medication [excepting
stable doses (greater than 3 months duration) of anticonvulsant medication for
seizure disorder or diphenhydramine for sleep
- prior history of aripiprazole treatment failure at appropriate doses and duration
- clinically significant low white blood cell count at baseline
Locations and Contacts
University of North Carolina, Chapel Hill, North Carolina 27599, United States
Duke University Medical Center, Durham, North Carolina 27705, United States
Additional Information
Starting date: August 2009
Last updated: February 7, 2014
|